每周股票复盘：维力医疗（603309）股东户数减少，上半年净利润增长14.17%

Core Viewpoint - The company, Weili Medical, has shown positive financial performance in the first half of 2025, with significant growth in revenue and net profit, while also planning to enhance production capacity through overseas factories [2][4][5]. Financial Performance - For the first half of 2025, Weili Medical reported a main revenue of 745 million yuan, an increase of 10.19% year-on-year [2] - The net profit attributable to shareholders reached 121 million yuan, up 14.17% year-on-year [2] - The second quarter alone saw a main revenue of 397 million yuan, reflecting an 8.16% increase year-on-year [2] - The company maintained a gross margin of 45.04% [2] Shareholder Changes - As of June 30, 2025, the number of shareholders decreased to 17,300, a reduction of 319, or 1.81% [1][6] - The average number of shares held per shareholder increased from 16,600 to 16,900, with an average holding value of 215,500 yuan [1] Product and Market Strategy - The company’s urology products have a gross margin exceeding 70%, driven by the successful market promotion of its flagship product, the stone removal sheath [4] - Weili Medical has intensified its overseas expansion efforts, establishing a professional team for international business development, leading to significant growth in export revenues [4] - The company is focusing on high-margin products in its research and development pipeline, which is expected to further increase the proportion of high-margin products in the future [4] Production Capacity and Automation - Currently, all major products are produced domestically across five cities, with production capacity nearing saturation [5] - To mitigate geopolitical risks, the company is constructing factories in Indonesia and Mexico, aimed at enhancing production capacity and automation for North and South American markets [5] Upcoming Events - Weili Medical will hold its first extraordinary general meeting of 2025 on August 15, 2025, to discuss multiple resolutions, including share repurchase and amendments to the company’s articles of association [7]